Transcranial magnetic stimulation, a non-invasive neuromodulation technique, uses magnetic pulses to influence neural activity in specific brain regions. Since receiving FDA approval in 2008 for major depressive disorder, TMS has grown in clinical utility, particularly for patients unresponsive to traditional pharmacological and psychotherapeutic interventions. Historically, determining the target site for TMS has relied on surface anatomical landmarks on the scalp, which serve as proxies for underlying brain structures. While pragmatically sound and easily accessible for widespread clinical use, this traditional approach lacks customization to the patient’s unique brain circuitry, potentially limiting therapeutic gains.

The innovation introduced by this study lies in leveraging functional magnetic resonance imaging (fMRI) to identify individualized treatment targets based on resting-state functional connectivity. This imaging modality measures synchronized activity patterns amongst disparate brain regions while subjects are at rest. By parsing these connectivity networks, the research team pinpointed precise loci within the brain circuits implicated in depression, thereby refining the spatial accuracy of stimulation. This neuroimaging foundation enables a more tailored intervention that accounts for the heterogeneity of depression at the circuit level.

Of particular note is the application of accelerated TMS (aTMS), which compresses multiple treatment sessions into a single day, thereby shortening the overall treatment course from several weeks to a mere week. This intensification not only improves patient convenience but may enhance neurobiological receptivity to stimulation by delivering more frequent pulses within a condensed timetable. The study set out to compare the clinical outcomes of aTMS when targets were defined by fMRI connectivity versus the established scalp-based targeting.

The trial enrolled 40 adult participants with moderate to severe treatment-resistant major depression, spanning a broad age range of 22 to 80 years. Each individual underwent pre-treatment fMRI scanning to delineate functional connectivity profiles. Subsequently, subjects were randomized to receive aTMS directed either at their individualized connectivity-based target or the conventional scalp-based target. Crucially, both patients and clinical raters were blinded to group assignments to mitigate bias.

One month post-treatment assessments revealed that the group receiving connectivity-guided aTMS demonstrated significantly greater alleviation of depressive symptoms compared to their scalp-based counterparts. These improvements were quantified using the Montgomery-Åsberg Depression Rating Scale (MADRS), a gold-standard clinician-administered instrument that sensitively captures changes in depression severity. Furthermore, the response rate — defined by clinically meaningful symptom reduction — was markedly higher in the connectivity group, with 80% responding versus 60% in the traditional targeting group, underscoring the potential clinical advantage of imaging-informed intervention.

This research builds upon prior explorations led by Joseph Taylor and colleagues, including investigations into imaging-based modulation of anxiety circuits within depressive populations, as recently reported in Molecular Psychiatry. These cumulative findings lend prospective support to the concept that precision neuroimaging can transcend theoretical neuroscience and play a direct role in augmenting therapeutic outcomes.

Taylor emphasizes the significance of closing the gap between neuroimaging research and tangible clinical benefit. Historically, the complexity and additional cost associated with imaging have created barriers to its routine clinical adoption for TMS guidance. This study represents a crucial step toward justifying such investment by empirically demonstrating a quantifiable benefit above conventional practice, a vital incentive for healthcare providers and payers considering integration of this technology.

Despite the promising results, the authors acknowledge particular study limitations, including the modest sample size and single-center study design, which may affect generalizability. They advocate for larger, multi-site trials to validate these early findings and explore durability of treatment effects over extended follow-up periods. Broadening the participant demographics will also be essential to ascertain the utility of connectivity-based targeting across diverse patient populations and varying clinical subtypes of depression.

This trial’s implications extend beyond depression, suggesting that functional brain imaging could inform individualized treatment strategies for a range of psychiatric disorders treatable by neuromodulation, including anxiety, obsessive-compulsive disorder, and post-traumatic stress disorder. As aTMS and neuroimaging technologies continue to evolve and become more accessible, the integration of connectivity-guided targeting holds promise for ushering in a new era of personalized psychiatry grounded in neurobiological precision.

In conclusion, the Mass General Brigham team’s randomized controlled trial provides compelling evidence that connectivity-based targeting via functional MRI can substantially enhance the antidepressant impact of accelerated TMS treatment in individuals with refractory depression. This approach offers a paradigm shift toward precision-guided neuromodulation, with the potential to improve patient outcomes and redefine clinical standards for brain stimulation therapies in psychiatric care.

Subject of Research: People

Article Title: Connectivity- versus scalp-based targeting of accelerated TMS for depression: A randomized trial

Web References:

• https://jamanetwork.com/journals/jamapsychiatry/fullarticle/10.1001/jamapsychiatry.2026.1100
• https://www.massgeneralbrigham.org/en/about/neuroscience-institute
• https://www.massgeneralbrigham.org/en/about/complex-psychiatric-care

References:
Taylor, J. et al. “Connectivity- versus scalp-based targeting of accelerated TMS for depression: A randomized trial,” JAMA Psychiatry, DOI: 10.1001/jamapsychiatry.2026.1100

Keywords:
Depression, Transcranial magnetic stimulation, Accelerated TMS, Functional magnetic resonance imaging, Functional connectivity, Neuroimaging-guided neuromodulation, Treatment-resistant depression, Personalized psychiatry, Montgomery-Åsberg Depression Rating Scale

Previous research had implicated opioid receptors in the brain as critical mediators of ketamine’s antidepressant properties. Building upon this, Dr. Conor Liston and Dr. Joshua Levitz employed highly sophisticated neurobiological techniques to precisely identify which subsets of these receptors ketamine targets. Their findings, recently published in the prestigious journal Cell, reveal that ketamine selectively binds to opioid receptors located on a population of interneurons within the prefrontal cortex – a brain hub central to mood regulation, cognition, and behavior. These interneurons function as master regulators, exerting inhibitory control over excitatory neurons and thereby modulating cortical output.

Under chronic stress conditions, these interneurons become hyperactive, excessively dampening the activity of pyramidal neurons in the prefrontal cortex, which is strongly associated with depressive phenotypes. Ketamine’s interaction with opioid receptors counteracts this excessive inhibitory signaling, transiently reducing interneuron activity. This disinhibition reactivates pyramidal neurons, effectively “reawakening” cortical circuits impaired in depression. Intriguingly, this cortical reactivation lasts only about 15 to 20 minutes, yet appears sufficient to initiate downstream cascades that mediate longer-lasting antidepressant effects.

Significantly, the team demonstrated that these early ketamine-induced changes could be mimicked in animal models by administering a combination of low doses of three distinct drugs targeting the same receptive pathway on interneurons. This pharmacological synergy holds promise for developing new treatments capable of eliciting rapid antidepressant responses without the problematic side effects associated with higher doses of ketamine. By leveraging this targeted multi-drug approach, lower individual doses reduce toxicity and the risk of addiction, enhancing clinical applicability.

Complementing these discoveries, a second collaborative study led by Dr. Levitz and Dr. Francis Lee, published in Science Advances, illuminated the molecular underpinnings responsible for sustaining ketamine’s longer-term therapeutic effects. Beyond its immediate actions on opioid receptors, ketamine was found to engage complex receptor cross-talk involving the tyrosine receptor kinase B (TrkB) and the metabotropic glutamate receptor 5 (mGluR5). This interaction fundamentally reshapes synaptic communication within the brain’s neural networks.

Ketamine’s antidepressant effect was long attributed to its antagonism of N-methyl-D-aspartate (NMDA) receptors; however, this new research identifies the critical role of mGluR5 receptors as co-conspirators in the sustained enhancement of neural connectivity. The release of brain-derived neurotrophic factor (BDNF), a neurotrophin pivotal for neuronal survival and plasticity, stimulates TrkB. This activation promotes physical associations between TrkB and mGluR5 receptors, orchestrating synaptic strengthening and stabilizing circuitry impaired during depression. Fascinatingly, this receptor interplay also triggers the internalization of mGluR5 receptors from the neuronal membrane, preventing excessive synaptic weakening and promoting resilient synaptic networks.

These findings represent a paradigm shift in conceptualizing antidepressant mechanisms, highlighting a bidirectional modulation of excitatory and inhibitory pathways and emphasizing the dynamic nature of synaptic plasticity. By promoting synaptic fortification while simultaneously curbing maladaptive synaptic weakening, the combined action of BDNF-TrkB and mGluR5 receptor pathways creates a neurochemical environment conducive to both immediate and sustained mood improvement.

In pursuit of clinical translation, Dr. Liston’s group is preparing to launch a trial investigating whether strategic combinations of low-dose medications—some already approved and known to be safe—can replicate ketamine’s antidepressant efficacy observed in preclinical models. This approach would potentially expedite bringing novel therapeutic options to patients suffering from refractory depression. Simultaneously, Drs. Lee and Levitz are examining whether augmenting low-dose ketamine treatment with agents targeting the mGluR5 receptor can preserve antidepressant benefits while minimizing undesirable effects.

This accelerated research trajectory owes much to the multidisciplinary expertise spanning neuroscience, psychiatry, molecular biology, and pharmacology. The integration of diverse scientific perspectives fosters holistic understanding and rapid innovation, a model that serves to bridge laboratory advances and patient care effectively. Such efforts emphasize precision medicine strategies rather than relying on empirical trial-and-error prescribing, marking a significant stride toward personalized psychiatry.

The excitement surrounding these studies is underscored by their potential to reshape therapeutic paradigms for one of the most challenging psychiatric conditions. They not only elucidate fundamental aspects of brain circuit regulation but also offer tangible avenues for refining treatments to be safer, faster acting, and more durable. Patients and clinicians alike stand to benefit from these cutting-edge insights, which promise to transform how depression is managed in clinical settings.

Ultimately, these groundbreaking investigations reframe ketamine not merely as an anesthesia-derived antidepressant with side effects but as a gateway to understanding and harnessing the brain’s intrinsic capacity for rapid recovery from depression. By disentangling the distinct phases of ketamine’s action—initial cortical disinhibition followed by longer-term synaptic remodeling—scientists are now equipped to design refined interventions that mirror the drug’s benefits without its drawbacks.

These advances embody a critical milestone in neuropsychiatric research, reinforcing the importance of mechanistic clarity and innovative pharmacological strategies in addressing mental health disorders. As this knowledge continues to expand and crystallize, the promise of truly transformative therapies for depression becomes increasingly attainable, offering renewed hope for millions worldwide burdened by this pervasive illness.

Subject of Research: Neurobiological mechanisms underlying ketamine’s rapid and sustained antidepressant effects

Article Title: Weill Cornell Medicine researchers elucidate ketamine’s targeted neural pathways and receptor interactions to develop rapid-acting, safer antidepressant therapies

News Publication Date: 2024-06

Web References:

• https://www.cell.com/cell/abstract/S0092-8674(26)00395-8
• https://www.science.org/doi/10.1126/sciadv.abcd1234 (example placeholder for Science Advances article)

References:
Supported by National Institute on Drug Abuse, National Institute of Mental Health, National Institute of Neurological Disorders and Stroke, Swedish Research Council, Brain & Behavior Research Foundation, Horizon Europe Framework Programme, and others.

Image Credits: Not provided.

Keywords: Ketamine, depression, antidepressant mechanisms, opioid receptors, prefrontal cortex, interneurons, BDNF, TrkB receptor, mGluR5 receptor, synaptic plasticity, rapid-acting antidepressants, treatment-resistant depression

Over a six-year period from 2018 to 2024, nearly 300 participants diagnosed with major depressive disorder were enrolled across three premier academic medical centers located in Toronto, Dallas, and San Diego. The rigorous double-blind, non-inferiority design of the trial enabled an objective, head-to-head comparison between MST and right unilateral ultra-brief pulse ECT, the latter currently regarded as one of the most effective interventions for severe depression resistant to pharmacological and psychotherapeutic modalities.

The central finding of this landmark investigation was that approximately 48% of patients in both treatment arms achieved a meaningful clinical response, indicating that MST matches the therapeutic potency of ECT in alleviating core depressive symptoms. What sets MST apart, however, is its ability to markedly reduce adverse cognitive consequences. Unlike ECT, which commonly results in post-treatment confusion and deficits in short- and long-term memory—side effects that paradoxically restrict its clinical use—MST employs targeted magnetic stimulation to induce therapeutic seizures, deliberately sparing critical brain regions involved in memory processing and cognitive function.

Dr. Daniel Blumberger, Senior Scientist at CAMH and co-lead of the study, emphasized the clinical significance of these findings by highlighting the balancing act between efficacy and safety in depression treatments. He elaborated that despite ECT’s undeniable efficacy, its cognitive side effects have been a persistent obstacle preventing many eligible patients from opting for this potentially life-saving intervention. MST offers a paradigm shift, potentially transforming the therapeutic landscape by providing equivalent antidepressant effects without the cognitive costs traditionally associated with seizure-inducing therapies.

The technical mechanism underlying MST centers on its utilization of rapidly alternating magnetic fields generated by specialized coils placed on the patient’s scalp. These fields induce controlled seizures that engage neural circuits implicated in mood regulation but do so with spatial precision that limits stimulation of hippocampal and other temporal structures essential for memory encoding and retrieval. This selective targeting distinguishes MST from the more diffuse electrical currents used in ECT, which indiscriminately activate a broader cerebral territory, contributing to cognitive impairment.

The trial’s robust design included comprehensive neuropsychological assessments administered pre- and post-treatment to quantitatively measure changes across multiple cognitive domains, including memory, attention, and executive function. Participants receiving MST exhibited significantly better preservation of memory performance, corroborating the theoretical advantages conferred by the focused magnetic induction approach. These cognitive outcomes could alleviate one of the major concerns deterring widespread use of seizure therapy in psychiatry, potentially broadening access to effective treatments for a population often marginalized by refractory symptoms.

Major depressive disorder remains a leading cause of disability worldwide, with up to one-third of patients failing to respond to conventional antidepressant medications and psychotherapy. For those individuals, ECT has remained a critical intervention, yet uptake is limited due to anxieties about cognitive side effects, social stigma, and the invasiveness of the procedure. MST’s improved safety profile, combined with its comparable efficacy, may address the unmet need for safer, tolerable neuromodulation strategies capable of delivering rapid and sustained antidepressant effects.

While the study’s results are promising, the authors caution that regulatory approval processes, professional training programs, and infrastructure development are essential next steps before MST can be integrated into mainstream psychiatric practice. Ongoing research is necessary to optimize stimulation parameters, understand long-term outcomes, and investigate MST’s applicability to other neuropsychiatric conditions with treatment-resistant profiles. Nonetheless, this trial establishes a foundational evidence base supporting MST as a viable and potentially preferred alternative to ECT.

Dr. Zafiris Daskalakis, Professor and Chair of Psychiatry at UC San Diego and co-principal investigator, stressed the transformative potential of MST if implemented broadly. He noted that this innovation could revolutionize brain stimulation therapies, shifting clinical paradigms toward modalities that emphasize cognitive preservation alongside symptom remission, ultimately enhancing patient experience and adherence.

Importantly, the study was funded by the United States National Institute of Mental Health, reflecting the high priority placed on developing safer and more effective psychiatric treatments. Additional equipment support was generously provided in kind by MagVenture, a company specializing in neurostimulation technologies, highlighting the collaborative effort between academic institutions and industry in advancing mental health care.

As the global medical community grapples with the complexity of severe depression and the limitations of current treatment options, the emergence of MST represents a beacon of hope, promising to expand the arsenal of effective, patient-centred interventions. With further validation and dissemination, MST could redefine standards of care, delivering life-changing relief without sacrificing cognitive integrity.

This landmark research not only delivers critical scientific insight but also embodies a compassionate approach to treating a profoundly disabling disorder. As mental health professionals and patients alike seek therapies that reconcile efficacy with safety, MST stands at the forefront, heralding a new era in the management of severe depression.

Subject of Research: People

Article Title: Confirmatory efficacy and safety trial of magnetic seizure therapy versus right unilateral ultra-brief electroconvulsive therapy in depression (CREST–MST): a randomised, double-blind, non-inferiority trial in Canada and the USA

News Publication Date: 15-Apr-2026

Web References:
http://dx.doi.org/10.1016/S2215-0366(26)00060-X

Keywords: Psychiatric disorders, Magnetic Seizure Therapy, Electroconvulsive Therapy, Major Depressive Disorder, Cognitive Safety, Neurostimulation, Randomized Controlled Trial, Treatment-Resistant Depression

Treatment-resistant depression remains one of the most intractable challenges in mental health, affecting an estimated 30% of individuals diagnosed with major depressive disorder. Unlike traditional antidepressants requiring weeks to take effect, ketamine acts swiftly, often alleviating symptoms within hours. However, this relief is typically fleeting, lasting days to just a couple of weeks, necessitating repeated dosing that presents clinical and safety issues. The biological underpinnings of this transient action have thus far evaded full elucidation.

The investigative team, led by Professor Takuya Takahashi and Dr. Waki Nakajima, homed in on the brain’s α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs). These receptors facilitate excitatory synaptic transmission and are central to ketamine’s psychoactive mechanisms. The scientists engineered a novel compound named K-4, a positive allosteric modulator that enhances AMPAR-mediated signals, hypothesizing it could yield more durable antidepressant effects.

Testing K-4 in Wistar Kyoto rats, an established animal model for TRD, the researchers noted that a single administration triggered rapid antidepressant-like responses extending for at least two weeks post-treatment. This duration notably surpasses that achieved by ketamine or previously known AMPAR modulators, suggesting a mechanistic breakthrough beyond mere receptor activation.

To decode the molecular basis of this prolonged efficacy, the team conducted gene expression profiling in the medial prefrontal cortex (mPFC), a brain region integral to mood regulation. They observed marked suppression of NOX-1 expression following K-4 treatment. NOX-1 is an NADPH oxidase enzyme responsible for generating reactive oxygen species (ROS), molecules that, when in excess, can instigate oxidative stress, neuronal damage, and impaired neural circuit functionality.

Further experiments combining ketamine with a NOX-1 specific inhibitor illustrated a synergistic effect, significantly extending ketamine’s antidepressant-like impact beyond its conventional window. This pharmacological approach was corroborated by genetic methods selectively diminishing NOX-1 levels in the mPFC, underscoring NOX-1’s role as a gatekeeper of antidepressant duration.

At the neural circuit level, both K-4 administration and NOX-1 inhibition tempered pathological burst firing within the lateral habenula, a brain structure known to foster depressive-like behavior. Additionally, these interventions normalized the excitatory-inhibitory balance in mPFC microcircuits, a critical factor believed to underlie sustained antidepressant efficacy and cognitive resilience.

Professor Takahashi emphasizes, “Our data illuminate novel molecular and circuit mechanisms maintaining antidepressant effects over time. This advances the field beyond symptom suppression to fostering durable neural circuit stability.” The findings forecast two strategic avenues: co-administering ketamine with NOX-1 inhibitors to amplify and prolong responses, and developing next-generation AMPAR modulators like K-4 as standalone therapeutics.

The study’s innovative approach addresses a profound clinical gap, offering fresh hope to millions grappling with refractory depression. Its implications extend beyond psychiatry, providing insight into how oxidative stress and excitatory synaptic modulation intersect to regulate brain plasticity and mood—core elements of mental health disorders.

In addition to their scientific contributions, the research team includes inventors of related patents on AMPAR-targeting compounds, with K-4 licensed through AMPAMETRY, Inc., reflecting a promising translation from bench to bedside. Their multidisciplinary work exemplifies how mechanistic neuroscience can inform precision therapies tailored to complex psychiatric conditions.

The study, published in the prestigious journal Molecular Psychiatry on March 23, 2026, reflects a bold and innovative chapter in depression research, harnessing molecular neuroscience to disrupt the persistent and debilitating cycles of treatment-resistant depression.

Subject of Research: Animals
Article Title: NADPH oxidase-1 suppression prolongs the antidepressant-like effect of Ketamine
News Publication Date: 23-Mar-2026
Web References: http://dx.doi.org/10.1038/s41380-026-03527-1
Image Credits: Professor Takuya Takahashi, Yokohama City University Graduate School of Medicine, Japan
Keywords: Treatment-resistant depression, ketamine, NADPH oxidase-1, NOX-1, AMPA receptors, K-4 compound, antidepressant duration, molecular psychiatry, reactive oxygen species, medial prefrontal cortex, lateral habenula, synaptic modulation

However, a pioneering study from researchers at UCLA Health is poised to revolutionize the delivery framework of TMS, introducing a significantly accelerated treatment protocol that condenses the course into just five consecutive days. This intensified regimen delivers five sessions each day, totaling twenty-five treatments within a remarkably shortened timeframe. The investigation, recently published in the Journal of Affective Disorders, retrospectively evaluated clinical outcomes from 175 patients categorized into two cohorts: one receiving the conventional daily regimen and the other undergoing this novel “5×5” accelerated protocol.

Crucially, the comparative analysis revealed no statistically significant differences in the reduction of depressive symptoms between the two treatment models at the conclusion of their respective courses. Patients administered the accelerated five-by-five protocol demonstrated symptom alleviation comparable to those who completed the six-week conventional schedule. This finding underscores the potential for a major paradigm shift in TMS delivery, greatly enhancing patient convenience without sacrificing therapeutic effectiveness.

From a neurophysiological perspective, TMS operates by generating brief magnetic fields via a coil placed over the scalp, inducing electric currents that modulate neuronal activity in targeted cortical areas, primarily the dorsolateral prefrontal cortex—an area deeply involved in mood regulation and executive functions. The standard treatment’s extended duration aims to promote neuroplastic adaptations gradually, stabilizing mood improvement over time. The success of the accelerated protocol indicates that intensive neuronal engagement within a condensed period may be sufficient to trigger similar neuroplastic benefits, a hypothesis inviting further mechanistic exploration.

One of the study’s most enlightening observations concerns a subgroup of patients from the accelerated treatment arm who did not exhibit immediate clinical improvement upon completing the five-day regimen. Notably, these patients experienced a significant delayed response, with an average 36% reduction in depressive symptom scores manifesting two to four weeks post-treatment. This delayed therapeutic effect highlights the importance of reframing clinical expectations and follow-up assessments when employing condensed TMS schedules, emphasizing that immediate post-treatment evaluations may underestimate true efficacy.

The implications for clinical psychiatry are profound. For numerous individuals hindered by the formidable logistical demands of daily, protracted clinic visits, the accelerated TMS approach offers a more accessible and less disruptive therapeutic alternative. It caters particularly to patients who might otherwise forgo or delay treatment due to occupational, familial, or geographical constraints. Additionally, it could potentially allow for more rapid cycles of interventions in acute cases, improving response timelines and overall patient outcomes.

Despite the promising results, the authors prudently acknowledge limitations inherent in their retrospective study design. The absence of randomization and control conditions necessitates cautious interpretation, and they emphasize the critical need for prospective, randomized controlled trials to rigorously validate accelerated TMS efficacy and safety. Such trials would elucidate long-term remission rates, optimal session frequency, and potential neurocognitive side effects, providing a robust evidence base for clinical practice guidelines.

Furthermore, conventional TMS protocols, with their longer course, continue to excel in certain long-term outcome measures, suggesting that while accelerated treatment is a viable alternative, it may not yet supplant traditional methods in all clinical contexts. Personalized treatment trajectories will likely become the future norm, tailoring TMS schedules to patient-specific factors such as illness severity, comorbidities, and logistical feasibility.

Beyond depression, UCLA researchers are expanding investigations into novel applications for TMS, including obsessive-compulsive disorder and chronic pain syndromes. These exploratory avenues position TMS at the forefront of next-generation brain-based therapies, potentially revolutionizing treatment across a spectrum of neuropsychiatric and pain disorders. The modality’s noninvasive nature and capacity for targeted neuromodulation offer unparalleled advantages in this evolving therapeutic landscape.

The study’s authors highlighted the importance of patient perseverance through the treatment process. Senior investigator Dr. Andrew Leuchter emphasized that patients who perceive minimal improvement immediately after accelerated TMS should remain optimistic, as significant benefits may emerge in subsequent weeks, reinforcing the temporal dynamics of neuroplastic changes induced by the therapy.

In conclusion, the advent of accelerated TMS represents a milestone in the evolution of neurostimulation treatments for depression. By demonstrating comparable efficacy within a compressed timeframe, this protocol holds the promise of transforming patient access and adherence, thereby expanding the therapeutic reach of this modality. Future research endeavors will determine how best to integrate accelerated TMS into clinical practice, optimize patient selection, and explore synergistic combinations with pharmacotherapies or psychotherapies to further enhance outcomes.

As the field advances, the intersection of innovative neuromodulation techniques with personalized medicine heralds a new era in the management of complex psychiatric disorders, offering hope to millions afflicted by depression and related conditions who previously had limited effective treatment options.

Subject of Research: People

Article Title: Efficacy of 5 × 5 accelerated versus conventional repetitive transcranial magnetic stimulation (rTMS) for treatment-resistant depression

News Publication Date: 23-Feb-2026

Web References: 10.1016/j.jad.2026.121345

Keywords: Depression, Affective disorders, Psychiatric disorders, Clinical psychology, Psychological science, Transcranial magnetic stimulation, Medical treatments

In the traditional clinical practice of TMS, clinicians have largely relied on historical reports linking lesion locations to behavioral or emotional symptoms, alongside neuroimaging studies highlighting dysfunction in frontal brain regions. This approach, while successful in many cases, necessarily narrows the scope of potential targets to a limited region of the brain—primarily the dorsolateral prefrontal cortex and adjacent prefrontal neuronal networks. These sites have been repeatedly validated as effective loci to alleviate symptoms in treatment-resistant depression and related illnesses. Yet, this focus raises the question: are there modifiable, posterior brain hubs implicated in psychiatric symptoms that remain unexplored by neuromodulation?

Emerging research suggests that the brain is a deeply interconnected organ, with psychiatric disorders reflecting dysfunction not only in frontal executive circuits but also in posterior regions such as the occipital cortex, precuneus, inferior parietal lobules, and cerebellum. These areas, traditionally associated with perceptual processes, self-referential thought, spatial cognition, and motor control, have gained recognition for their involvement in mood regulation, attention, and cognitive integration. Despite this, they have been conspicuously understudied as possible TMS targets in clinical trials, leaving a gap in both our understanding of neuropsychiatric circuitry and the full therapeutic potential of TMS.

In a timely and insightful Perspective article, McCalley and colleagues illuminate the landscape of posterior brain targets in neuropsychiatric disorders and propose an expansion of TMS paradigms. They argue that broadening target selection to incorporate these posterior regions could unlock novel therapeutic avenues that engage distinct neural networks, potentially offering relief for patients who are resistant to conventional prefrontal stimulation. This shift necessitates both a careful examination of the functional neuroanatomy involved and rigorous testing of safety and efficacy in future clinical settings.

The occipital cortex, long associated primarily with visual processing, has recently been implicated in affective disorders due to its connectivity with limbic and frontal brain regions. Neuroimaging studies have demonstrated altered activity patterns in the occipital lobe in individuals with depression and anxiety, revealing hyperconnectivity or hypoconnectivity that correlates with symptom severity. Targeting the occipital cortex with TMS could modulate early sensory processing, which in turn might influence higher-order cognitive and emotional circuits. Such an approach challenges the traditional focus on “executive” regions and underscores the role of sensory information processing in mood regulation.

Equally compelling is the precuneus, a central node in the default mode network (DMN), known for its role in self-referential thinking, episodic memory retrieval, and conscious awareness. Aberrant DMN activity has been robustly linked to depressive rumination and other maladaptive cognitive patterns seen in psychiatric illnesses. The precuneus’s accessibility to magnetic stimulation offers a tantalizing target to reshape network dynamics associated with negative self-focus, potentially alleviating persistent depressive symptoms or anxiety disorders. Early pilot studies hint at the feasibility of modulating this region noninvasively, though comprehensive clinical trials are warranted.

The inferior parietal lobules represent another posterior cortical area that holds therapeutic promise. These brain regions integrate multisensory information and contribute to attentional control and sensorimotor integration. Dysfunctions here have been observed in schizophrenia and mood disorders, where patients manifest aberrant perception, attentional bias, or impaired reality monitoring. By leveraging TMS to recalibrate activity in the inferior parietal lobules, clinicians may restore balance within distributed cortical networks, improving both cognitive and affective symptoms. However, the intricacy of this region’s functions requires precise targeting and modulation protocols to avoid undesired side effects.

Perhaps most intriguingly, the cerebellum—a structure historically relegated to motor coordination—has surfaced as a critical player in the regulation of emotion and cognition. The cerebellum is richly interconnected with the prefrontal cortex, limbic system, and associative sensory areas, and its involvement in psychiatric disorders such as depression, bipolar disorder, and autism spectrum conditions is increasingly recognized. Preliminary TMS studies have begun to explore cerebellar stimulation, noting possible benefits in mood stabilization and cognitive enhancement. This new frontier of neuromodulation could redefine therapeutic boundaries and challenge preconceived notions of localized brain function.

While posterior TMS targets offer exciting prospects, several technical and safety considerations must be addressed in their clinical implementation. The unique neuroanatomy and deeper cortical positioning of some posterior regions necessitate refined coil designs and stimulation parameters to achieve effective yet safe neuromodulation. In addition, the functional heterogeneity within posterior regions requires careful mapping to avoid off-target effects that could exacerbate symptoms or trigger unintended cognitive disruptions. Long-term studies will be critical to establish optimal dosing, session frequency, and durability of therapeutic gains.

Another challenge lies in integrating multi-modal imaging techniques, such as functional MRI, diffusion tensor imaging, and magnetoencephalography, to accurately identify suitable posterior targets based on individual neurocircuitry profiles. Personalized medicine approaches, combining advanced neuroimaging with computational modeling of electromagnetic field distribution, could tailor TMS protocols to each patient’s unique brain architecture. This precision medicine paradigm promises to maximize efficacy while minimizing adverse effects, heralding a new age in psychiatric treatment.

The few existing clinical trials investigating posterior TMS targets have yielded encouraging but preliminary results. Some studies targeting the occipital cortex have shown improvements in visual processing and mood symptoms, while cerebellar stimulation has demonstrated potential in enhancing executive function and reducing anxiety. These nascent data suggest that posterior TMS might complement or, in some cases, surpass traditional prefrontal approaches, especially for patients with resistant or atypical presentations. Nonetheless, replication in larger, randomized controlled studies remains an essential next step.

Combining posterior TMS targets with established prefrontal stimulation protocols could provide synergistic effects by engaging both sensory and executive neural networks. Multi-site stimulation paradigms might modulate dysfunctional connectivity more holistically than unilateral targeting, offering a richer therapeutic landscape. However, this complexity mandates careful clinical design to avoid overstimulation or desynchronization of critical neural circuits.

Ethically, expanding TMS beyond the frontal cortex compels the psychiatric community to balance innovation with caution. Given the emerging nature of posterior target research, informed consent processes must transparently communicate the experimental status of these interventions and potential unknown risks. Enhanced monitoring for adverse events and cognitive side effects will be necessary, alongside long-term follow-up to ascertain sustained benefits or late-emerging complications.

The consideration of posterior brain regions for neuromodulation reflects a broader paradigm shift in psychiatry—one that embraces the brain’s intrinsic network architecture rather than isolated loci. Modern psychiatric disorders are increasingly conceptualized as circuitopathies, involving complex interplay across distributed brain regions. TMS targeting posterior cortical and cerebellar nodes exemplifies this network-based approach, leveraging evolving neurobiological insights to refine therapeutic strategies.

In conclusion, the expansion of TMS applications to include posterior brain targets heralds a promising avenue for addressing unmet clinical needs in psychiatric treatment. While frontal lobe stimulation has established a robust therapeutic foundation, integrating occipital, parietal, precuneal, and cerebellar targets may enrich outcomes and offer new hope for patients with refractory conditions. Continued interdisciplinary collaboration among neuroscientists, clinicians, and engineers will be crucial to fully realize this potential and translate neuroanatomical discoveries into impactful, patient-centered therapies.

The contributions of McCalley et al. firmly anchor this emerging discussion in a rigorous scientific framework, emphasizing the importance of careful, methodical exploration of posterior neural hubs. Their Perspective calls on the psychiatric and neuromodulation communities to venture beyond conventional boundaries in pursuit of more comprehensive, network-oriented treatments. As research accelerates in this domain, TMS may well transform from a predominantly frontal cortex tool into an exquisite, multi-target instrument capable of reshaping the future of mental health care.

Subject of Research:
Transcranial magnetic stimulation targeting posterior brain regions for psychiatric disorder treatment.

Article Title:
Illuminating posterior targets for transcranial magnetic stimulation beyond the prefrontal cortex.

Article References:

McCalley, D.M., Sanderson, L.L., Dowdle, L.T. et al. Illuminating posterior targets for transcranial magnetic stimulation beyond the prefrontal cortex.
Nat. Mental Health (2025). https://doi.org/10.1038/s44220-025-00433-3

Image Credits: AI Generated